infohep news

• Finance, funding & health economics

  HCV is a major reason for healthcare utilisation in the United States

  Michael Carter / 24 June 2014

  People with hepatitis C virus (HCV) infection are significant users of healthcare services in the United States, according to research published in the online edition of Clinical Infectious Diseases. Between 2001 and 2010, ...

• Finance, funding & health economics

  Low uptake of HCV treatment in England will lead to substantial disease burden by 2035

  Michael Carter / 24 June 2014

  Only 3% of people with chronic hepatitis C virus (HCV) are treated for their infection each year in England, according to research published in the Journal of Hepatology. The current uptake of ...

• Fatigue

  Sustained response to treatment reduces fatigue in people with hepatitis C

  Keith Alcorn / 30 May 2014

  Curative treatment that eliminates hepatitis C virus (HCV) from the body can reduce central fatigue, one of the most concerning symptoms associated with chronic hepatitis C, according to research presented at the ...

• Treatment in liver transplanted

  Sofosbuvir + ribavirin is safe and effective for HCV recurrence after liver transplantation

  Liz Highleyman / 29 May 2014

  An interferon-free combination of sofosbuvir (Sovaldi) plus ribavirin taken for up to 24 weeks led to sustained virological response in 70% of liver transplant recipients with hepatitis C virus (HCV) recurrence, according to ...

• Interferon-free regimens

  Sofosbuvir + ribavirin for 24 weeks is highly effective against HCV genotype 4

  Liz Highleyman / 28 May 2014

  A 24-week regimen of sofosbuvir (Sovaldi) plus ribavirin cured 93% of people with hard-to-treat hepatitis C virus genotype 4, though treatment for only 12 weeks was not as effective, according to a ...